0.332
Matinas Biopharma Holdings Inc stock is traded at $0.332, with a volume of 199.00M.
It is up +37.53% in the last 24 hours and down -48.32% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.2414
Open:
$0.38
24h Volume:
199.00M
Relative Volume:
56.60
Market Cap:
$2.13M
Revenue:
$1.10M
Net Income/Loss:
$-11.23M
P/E Ratio:
-0.164
EPS:
-2.025
Net Cash Flow:
$-6.61M
1W Performance:
+5.50%
1M Performance:
-48.32%
6M Performance:
-53.89%
1Y Performance:
-64.30%
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MTNB
Matinas Biopharma Holdings Inc
|
0.332 | 1.55M | 1.10M | -11.23M | -6.61M | -2.025 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Matinas BioPharma Holdings Inc - TradingKey
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket - Benzinga
Matinas BioPharma Holdings Inc (MTNB) Institutional Confidence - TradingKey
Matinas BioPharma Holdings Inc (MTNB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Matinas BioPharma Holdings Inc (MTNB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Matinas BioPharma Holdings Inc (MTNB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Matinas Biopharma Holdings, Inc. Revenue Breakdown – AMEX:MTNB - TradingView
Trending Stocks Today | Matinas BioPharma Surges 44.65% Post-Market - Moomoo
Matinas BioPharma Ends At-The-Market Sales Agreement - TipRanks
Matinas BiopharmaBtig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026SEC Filing - TradingView
Matinas BioPharma $50 Million ATM Program With BTIG Terminated With No Penalties - TradingView
Matinas BioPharma Holdings Inc (MTNB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate M - Hydrogen Central
[425] Matinas BioPharma Holdings, Inc. Business Combination Communication - Stock Titan
Matinas BioPharma Holdings Inc (NYSE: MTNB) Share Price, MTNB Stock News, MTNB Share Price & Updates - Kalkine
Matinas BioPharma (NYSE: MTNB) to combine with GH Power in new Ontario holdco - Stock Titan
GH Power Goes Public via Matinas BioPharma Merger - Fuel Cells Works
GH Power To Go Public Through Business Combination With Matinas BioPharma - Pulse 2.0
Nasdaq Surges Over 100 Points; Bank of America Earnings Top Views - Sahm
Hezbay builds 9.54% position in Matinas BioPharma (MTNB) - Stock Titan
Matinas BioPharma forms business tie-up with GH Power to create clean energy and green hydrogen company - ROI-NJ
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
United StatesLowenstein Represents Matinas BioPharma In Strategic Business Combination With GH Power And Divestiture Of Matinas BioPharma Nanotechnologies, Inc. - Mondaq
GH Power to go public via merger with Matinas BioPharma By Investing.com - Investing.com Nigeria
GH Power to go public via Matinas BioPharma merger - scanx.trade
GH Power to go public via merger with Matinas BioPharma - Investing.com
GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma - Yahoo Finance
Matinas BioPharma to Merge with GH Power, Selling LNC Platform to Azurity in Major Clean Energy & Pharma Deal - Minichart
Matinas BioPharma to Merge with GH Power International - TipRanks
Matinas BioPharma (MTNB) Engages in Strategic Business Combinati - GuruFocus
Matinas BioPharma (NYSE: MTNB) plans GH Power merger and $21.5M Azurity sale - Stock Titan
Matinas BioPharma (NYSE: MTNB) plans GH Power merger and $21.5M Azurity asset sale - Stock Titan
Press Release: Matinas BioPharma Announces Strategic Business Combination With GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Produ - Moomoo
Biotech Matinas pivots into green hydrogen as GH Power goes public in NYSE deal - Stock Titan
Matinas BioPharma Company Profile & Introduction - Moomoo
MSN Money - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionCan Fite Biopharma (AMEX:CANF), Atlantic - Benzinga
Matinas Biopharma Shares Edge Higher, Approaching Key Resistance LevelIV Expansion Alert - DonanımHaber
Price to earnings forward of Matinas Biopharma Holdings, Inc. – AMEX:MTNB - TradingView
Price to earnings forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView
Price to book forward of Matinas Biopharma Holdings, Inc. – AMEX:MTNB - TradingView
Price to sales forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView
Enterprise value to revenue forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView
Enterprise value to EBIT forward of Matinas BioPharma Holdings, Inc. – GETTEX:6LJ0 - TradingView
Matinas BioPharma receives NYSE delisting plan extension - Investing.com UK
Matinas BioPharma receives NYSE delisting plan extension By Investing.com - Investing.com Nigeria
Matinas BioPharma Receives NYSE American Non-Compliance Notice, Granted Plan Period to Regain Listing Standards - Minichart
Matinas BioPharma (MTNB) Faces NYSE Equity Compliance Challenge - GuruFocus
Matinas BioPharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):